Fox Run Management L.L.C. Takes $1.18 Million Position in Bristol Myers Squibb Company $BMY

Fox Run Management L.L.C. acquired a new position in Bristol Myers Squibb Company (NYSE:BMY) in the 3rd quarter, HoldingsChannel reports. The fund acquired 26,138 shares of the biopharmaceutical company’s stock, valued at approximately $1,179,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BMY. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb during the second quarter worth about $25,000. Harbor Capital Advisors Inc. lifted its stake in shares of Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 313 shares in the last quarter. Total Investment Management Inc. bought a new position in Bristol Myers Squibb in the 2nd quarter worth approximately $38,000. Twin Peaks Wealth Advisors LLC bought a new position in Bristol Myers Squibb in the 2nd quarter worth approximately $40,000. Finally, Mark Sheptoff Financial Planning LLC grew its stake in Bristol Myers Squibb by 233.3% in the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 700 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $61.32 on Thursday. The stock has a market cap of $124.88 billion, a price-to-earnings ratio of 17.78, a PEG ratio of 0.18 and a beta of 0.29. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The business has a 50-day simple moving average of $56.66 and a 200 day simple moving average of $50.33. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The business had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business’s revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Leerink Partners increased their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $52.00 to $61.00 in a report on Monday, December 15th. Piper Sandler restated an “overweight” rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday. Citigroup upped their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Nine analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $60.71.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.